Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in good shape more than enough to tolerate FCR therapy, may still be excellent candidates to the latter, with the advantage staying this treatment is usually done in 6 months when ibrutinib has to be taken indefinitely. This feature https://jareduitcl.daneblogger.com/30535723/top-latest-five-mbl77-urban-news